New drug development is a long and arduous journey. To support the significant costs of developing new stem cell drugs, we've adopted a strategy of steady, deep-rooted growth in Taiwan. By building a solid foundation and continuously focusing on quality improvement, we use our core stem cell technology platform to generate cash flow through stem cell nutraceuticals and stem cell banking services. This approach creates a stable operating model that funds our new drug development efforts.